MA45124B1 - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents

Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Info

Publication number
MA45124B1
MA45124B1 MA45124A MA45124A MA45124B1 MA 45124 B1 MA45124 B1 MA 45124B1 MA 45124 A MA45124 A MA 45124A MA 45124 A MA45124 A MA 45124A MA 45124 B1 MA45124 B1 MA 45124B1
Authority
MA
Morocco
Prior art keywords
treatment
antibody
biomarker
level
sample
Prior art date
Application number
MA45124A
Other languages
English (en)
French (fr)
Other versions
MA45124A (fr
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA45124A publication Critical patent/MA45124A/fr
Publication of MA45124B1 publication Critical patent/MA45124B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA45124A 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients MA45124B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Publications (2)

Publication Number Publication Date
MA45124A MA45124A (fr) 2017-12-07
MA45124B1 true MA45124B1 (fr) 2021-05-31

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45124A MA45124B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
MA57021A MA57021B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA57021A MA57021B1 (fr) 2016-05-30 2017-05-30 Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients

Country Status (27)

Country Link
US (2) US20190195879A1 (OSRAM)
EP (2) EP3465214B1 (OSRAM)
JP (2) JP7066639B2 (OSRAM)
KR (1) KR102416144B1 (OSRAM)
CN (2) CN115932265A (OSRAM)
AU (1) AU2017272608B2 (OSRAM)
BR (1) BR112018074603A2 (OSRAM)
CY (1) CY1124768T1 (OSRAM)
DK (2) DK3916392T3 (OSRAM)
EA (1) EA201892542A1 (OSRAM)
ES (2) ES2878156T3 (OSRAM)
FI (1) FI3916392T3 (OSRAM)
HR (2) HRP20210938T1 (OSRAM)
HU (2) HUE054860T2 (OSRAM)
IL (1) IL263103B2 (OSRAM)
LT (2) LT3916392T (OSRAM)
MA (2) MA45124B1 (OSRAM)
MD (2) MD3465214T2 (OSRAM)
MX (2) MX388502B (OSRAM)
PL (2) PL3465214T3 (OSRAM)
PT (2) PT3916392T (OSRAM)
RS (2) RS62155B1 (OSRAM)
SG (2) SG11201810159TA (OSRAM)
SI (2) SI3916392T1 (OSRAM)
SM (2) SMT202400204T1 (OSRAM)
WO (1) WO2017207574A1 (OSRAM)
ZA (2) ZA201808647B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
LT3532098T (lt) 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MA55794A (fr) * 2019-05-03 2022-03-09 Morphosys Ag Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk
KR20220103969A (ko) * 2019-10-31 2022-07-25 모르포시스 아게 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
BR112023010885A2 (pt) * 2020-12-04 2023-10-03 Incyte Corp Terapia de combinação de anti-cd19

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101063278B1 (ko) 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR101335798B1 (ko) * 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
ATE501436T1 (de) 2006-09-13 2011-03-15 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
SG190254A1 (en) 2010-11-15 2013-06-28 Medimmune Llc Combination therapy for b cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20200058583A (ko) 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
PL2744826T3 (pl) * 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i analogiem puryny
WO2013090478A1 (en) * 2011-12-12 2013-06-20 Pikamab, Inc Predicting responsiveness to antibody maintenance therapy
EP3110445A4 (en) * 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CN106794231A (zh) * 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
WO2016005548A1 (en) 2014-07-11 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers

Also Published As

Publication number Publication date
SI3916392T1 (sl) 2024-10-30
HRP20240670T1 (hr) 2024-09-27
AU2017272608A1 (en) 2018-12-06
HUE067450T2 (hu) 2024-10-28
AU2017272608B2 (en) 2023-08-10
MD3916392T2 (ro) 2024-10-31
NZ748468A (en) 2025-05-30
PL3465214T3 (pl) 2021-12-20
JP7511806B2 (ja) 2024-07-08
SMT202100291T1 (it) 2021-07-12
EA201892542A1 (ru) 2019-06-28
FI3916392T3 (fi) 2024-06-03
JP2019519770A (ja) 2019-07-11
ZA201808647B (en) 2021-05-26
JP7066639B2 (ja) 2022-05-13
MX388502B (es) 2025-03-20
ZA202100296B (en) 2025-05-28
CN109313194A (zh) 2019-02-05
EP3916392A1 (en) 2021-12-01
PL3916392T3 (pl) 2024-09-23
US20220283166A1 (en) 2022-09-08
SG10201911958SA (en) 2020-02-27
DK3916392T3 (da) 2024-05-21
MX2021014963A (es) 2022-02-24
CN115932265A (zh) 2023-04-07
EP3465214A1 (en) 2019-04-10
WO2017207574A1 (en) 2017-12-07
PT3465214T (pt) 2021-06-30
CA3025823A1 (en) 2017-12-07
KR20190013980A (ko) 2019-02-11
PT3916392T (pt) 2024-06-04
DK3465214T3 (da) 2021-05-31
CY1124768T1 (el) 2022-11-25
BR112018074603A2 (pt) 2019-03-19
IL263103B2 (en) 2023-10-01
KR102416144B1 (ko) 2022-07-04
LT3465214T (lt) 2021-10-11
ES2878156T3 (es) 2021-11-18
IL263103B1 (en) 2023-06-01
MA45124A (fr) 2017-12-07
SMT202400204T1 (it) 2024-09-16
HUE054860T2 (hu) 2021-10-28
JP2022119764A (ja) 2022-08-17
MA57021B1 (fr) 2024-05-31
MX2018014702A (es) 2019-10-02
US20190195879A1 (en) 2019-06-27
MD3465214T2 (ro) 2021-09-30
EP3916392B1 (en) 2024-05-01
LT3916392T (lt) 2024-08-26
CN109313194B (zh) 2022-11-04
RS65540B1 (sr) 2024-06-28
SG11201810159TA (en) 2018-12-28
ES2981046T3 (es) 2024-10-07
HRP20210938T1 (hr) 2021-09-03
EP3465214B1 (en) 2021-04-28
RS62155B1 (sr) 2021-08-31
SI3465214T1 (sl) 2021-12-31
IL263103A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
MA45124B1 (fr) Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
Varettoni et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms
Lampson et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Holmgren et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.
Palm et al. The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers
Sugimori et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol‐anchored protein among patients with bone marrow failure
Fan et al. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation
Kim et al. CD79B and MYD88 mutations in diffuse large B-cell lymphoma
Chen et al. Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling
Heidel et al. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
Pan et al. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy
Odani et al. Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5* 01: 05 allele in scleroderma patients with interstitial lung disease
Shinohara et al. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction
Akhter et al. CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series
Sippert et al. Association of duffy blood group gene polymorphisms with IL8 gene in chronic periodontitis
Tambur et al. HLA-DQ barrier: Effects on cPRA calculations
US10725029B2 (en) Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample
Angelot‐Delettre et al. Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis
Carbone et al. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy
Isidro-Hernández et al. Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice
Dehmel et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome
Hannula-Jouppi et al. Genetic susceptibility to non-necrotizing erysipelas/cellulitis
Sun et al. Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration
Hartling et al. Gene variation in IL-7 receptor (IL-7R) α affects IL-7R response in CD4+ T cells in HIV-infected individuals
Yamauchi et al. Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma